Biodegradable polymer nanospheres can be utilized for the controlled release of potent vaccine antigens. There are significant barriers to commercialization with conventional polymer nanospheres technologies. Aphios' use of SuperFluids™ reduces exposure of vaccine antigens to potentially denaturing organic solvents such as methylene chloride and ethyl acetate, and improves the stability of vaccine antigens in the body at ambient temperature for long periods, thereby enhancing the capability of nanoencapsulated vaccine antigens to induce the production of protective and neutralizing antibodies. Other benefits include adjuvant stimulation of the immune system by the nanospheres, and improved shelf stability of the vaccine preparation.
This controlled release vaccine delivery technology, SFS-PNS, has the capability to deliver different types and combinations of HIV or Influenza vaccine candidates including whole inactivated virus particles, DNA plasmids and/or subunit protein antigens such as recombinant protein antigen (rPA) used in anthrax vaccines.
Aphios® Corporation is a green biotechnology company developing enabling technology platforms for improved drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, Aphios is developing enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and central nervous system disorders, such as Alzheimer's disease.
The Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services, supports the advanced research, development, acquisition, and stockpiling of medical countermeasures (drugs, biological therapeutics, vaccines, diagnostics, and non-pharmaceutical countermeasures) against Chemical, Biological, Radiological, and Nuclear (CBRN) WMD threats, pandemic influenza, and emerging infectious diseases.